Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
about
Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapyHeat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of CancerMelanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyDendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironmentSpecific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasisProphylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesTumor cell lysates as immunogenic sources for cancer vaccine designTherapeutic cancer vaccines and combination immunotherapies involving vaccinationDendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentThe vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.Formulation of dacarbazine-loaded cubosomes-part I: influence of formulation variables.Formulation of dacarbazine-loaded Cubosomes--part II: influence of process parameters.Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.Advanced malignant melanoma: immunologic and multimodal therapeutic strategiesMaturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses.Dendritic cell-based human immunodeficiency virus vaccine.Early tumor dissemination, but late metastasis: insights into tumor dormancy.Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells.PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisMulticenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanomaFormulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization.Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.Expression of ESE-3 isoforms in immunogenic and tolerogenic human monocyte-derived dendritic cells.The curcumin analog DM-1 induces apoptotic cell death in melanoma.Dendritic cell subsets in health and disease.Optimizing dendritic cell-based approaches for cancer immunotherapyHSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.
P2860
Q24598856-1EEF621C-0B5D-4969-8C38-1853B259ED1AQ26747392-6CD7210F-3643-4B76-BEA5-817E166881A7Q26798404-685D8AC7-8E8A-4073-AA6F-7E68BC828C53Q27000318-2074572A-5945-47DB-BFD1-22CD1CD9C710Q27310303-3DF7422C-C1FD-4445-BAE9-8F8A1BA3C0F5Q27323878-95F01CC2-0F00-49B7-9E6F-F8B46B318CA3Q27345217-A29E9D0E-4E44-4D80-B2AA-1FE077EF3771Q28083469-D939454B-BA8D-40C2-961C-730140693B17Q28397609-53FF122A-785F-4B34-8E28-1A7842BBA277Q30318566-6AD25B44-D338-4AB8-B0AF-B5AED64D7C63Q30415355-4D306E40-6ABB-4C7B-B507-240CFD9D99AEQ30423165-9A63503F-2D84-4FA7-96BC-27F368801F0DQ30434822-7CFB514E-8293-49C5-9AC0-51AF9ACD625EQ30846001-ABB0B5B9-3E7A-40EA-8DD7-1720DB25A06EQ33424674-60FB025B-E8BE-4627-B934-BA78869FFCC8Q33573423-70B18A12-B4F7-4E67-9A96-2C3322FCA21AQ33573499-2717563E-FEBA-4F64-B9C0-8F4412D4983EQ33584637-4489F39F-4AAF-4F0B-A0D0-A1AAF7C33D1FQ33618936-F0E56C36-8F17-44A2-B879-BFEE2DFE7B29Q33717891-202E89EF-3875-4765-85DB-832352F3D6B1Q33786246-FBE6628B-7774-4A1B-A1DE-C3F6394BB1E4Q33874652-486EB885-08B5-45F4-9634-BD9390B8D10FQ33882975-65904BE6-CFC5-41B2-A9C0-58A5069877AFQ34020065-A0E1C3F8-E4BF-407E-AC37-543C8E66257CQ34067493-7221C975-4151-440B-B7AC-9AF40B52AC5FQ34124931-64E2A36B-4A8A-4FDD-ABA0-E6417840E796Q34170003-481382DC-DFBA-4B9E-B1ED-C796DFDC7CE8Q34198563-79B87190-228E-4C89-BC4C-7A0972686776Q34280372-B00AEF51-5155-43C9-B745-2C7D33E12CC1Q34329143-A52FA339-37BB-453B-A60F-3A3CD62DC89FQ34347631-E6A8D96A-D52A-425E-A319-285AD7469705Q34490196-B934B43E-9A13-453A-9092-974B4F4D9BDBQ34566244-EA0E3C49-7C4F-4EEF-B3AE-35F263D02227Q34582889-C047BD2F-C3DC-4647-A76D-808B5F9D9357Q34637535-1972B169-CBF5-44E0-9A7C-584F50D02185Q35009889-973DEC69-ED73-4518-B18E-86222CECB95DQ35161543-E3F38FF4-D6F0-4B8E-9983-24F06C4F2849Q35207523-764EB76E-5C3B-4233-8BE8-05DBF2768DAFQ35250795-7E99BEF7-FBDE-4815-A399-B02066370BBAQ35294382-91C74A6B-6A60-4976-95EC-2401E8C4553B
P2860
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Dacarbazine (DTIC) versus vacc ...... e DC study group of the DeCOG.
@en
type
label
Dacarbazine (DTIC) versus vacc ...... e DC study group of the DeCOG.
@en
prefLabel
Dacarbazine (DTIC) versus vacc ...... e DC study group of the DeCOG.
@en
P2093
P356
P1433
P1476
Dacarbazine (DTIC) versus vacc ...... e DC study group of the DeCOG.
@en
P2093
A Tüttenberg
B Schuler-Thurner
C Zimpfer-Rechner
D Schadendorf
DC study group of the DeCOG
E-B Bröcker
F O Nestle
P2860
P304
P356
10.1093/ANNONC/MDJ138
P577
2006-01-17T00:00:00Z